Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Quantitative Health Sciences & Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Acta Oncol. 2022 Sep;61(9):1064-1068. doi: 10.1080/0284186X.2022.2107402. Epub 2022 Oct 18.
Mediastinal radiation is associated with increased risk of myocardial infarction (MI) among non-Hodgkin lymphoma (NHL) survivors.
To evaluate how preexisting cardiovascular risk factors (CVRFs) modify the association of mediastinal radiation and MI among a national population of NHL survivors with a range of CVRFs.
Using Danish registries, we identified adults diagnosed with lymphoma 2000-2010. We assessed MI from one year after diagnosis through 2016. We ascertained CVRFs (hypertension, dyslipidemia, and diabetes), vascular disease, and intrinsic heart disease prevalent at lymphoma diagnosis. We used multivariable Cox regression to test the interaction between preexisting CVRFs and receipt of mediastinal radiation on subsequent MI.
Among 3151 NHL survivors (median age 63, median follow-up 6.5 years), 96 were diagnosed with MI. Before lymphoma, 32% of survivors had ≥1 CVRF. 8.5% of survivors received mediastinal radiation. In multivariable analysis, we found that mediastinal radiation (HR = 1.96; 95% CI = 1.09-3.52), and presence of ≥1 CVRF (HR = 2.71; 95% CI = 1.77-4.15) were associated with an increased risk of MI. Although there was no interaction on the relative scale ( = 0.14), we saw a clinically relevant absolute increase in risk for patients with CVRF from 10-year of MI of 10.5% without radiation to 29.5% for those undergoing radiation.
Patients with CVRFs have an importantly higher risk of subsequent MI if they have mediastinal radiation. Routine evaluation of CVRFs and optimal treatment of preexisting cardiovascular disease should continue after receiving cancer therapy. In patients with CVRFs, mediastinal radiation should only be given if oncologic benefit clearly outweighs cardiovascular harm.
纵隔放疗会增加非霍奇金淋巴瘤(NHL)幸存者心肌梗死(MI)的风险。
评估在具有多种心血管危险因素(CVRF)的 NHL 幸存者中,预先存在的心血管危险因素(CVRF)如何改变纵隔放疗与 MI 之间的关联。
使用丹麦登记处,我们确定了 2000 年至 2010 年诊断为淋巴瘤的成年人。我们从诊断后一年到 2016 年评估 MI。我们确定了在淋巴瘤诊断时存在的 CVRF(高血压、血脂异常和糖尿病)、血管疾病和固有心脏病。我们使用多变量 Cox 回归检验预先存在的 CVRF 与纵隔放疗后 MI 的交互作用。
在 3151 名 NHL 幸存者中(中位年龄 63 岁,中位随访 6.5 年),有 96 人被诊断为 MI。在淋巴瘤之前,32%的幸存者有≥1 种 CVRF。8.5%的幸存者接受了纵隔放疗。在多变量分析中,我们发现纵隔放疗(HR=1.96;95%CI=1.09-3.52)和存在≥1 种 CVRF(HR=2.71;95%CI=1.77-4.15)与 MI 风险增加相关。尽管相对比例上没有交互作用( = 0.14),但我们发现接受纵隔放疗的患者,在 CVRF 存在的情况下,10 年 MI 的风险绝对增加,从无放疗时的 10.5%增加到 29.5%。
有 CVRF 的患者如果接受纵隔放疗,随后发生 MI 的风险会显著增加。在接受癌症治疗后,应继续常规评估 CVRF 并对已存在的心血管疾病进行最佳治疗。对于有 CVRF 的患者,如果肿瘤获益明显超过心血管危害,才应给予纵隔放疗。